A J Olyaei

Summary

Affiliation: Oregon Health and Science University
Country: USA

Publications

  1. ncbi request reprint HMG-CoA reductase inhibitors in chronic kidney disease
    A Olyaei
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Mail Code CR9 4, Portland, OR, 97201, USA
    Am J Cardiovasc Drugs 13:385-98. 2013
  2. doi request reprint A quantitative approach to drug dosing in chronic kidney disease
    Ali J Olyaei
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Blood Purif 31:138-45. 2011
  3. ncbi request reprint Cardiovascular complications of immunosuppressive agents in renal transplant recipients
    Ali J Olyaei
    Oregon Health Sciences University, Division of Nephrology, Hypertension, 3181 SW Sam Jackson Park Road, Mail Code CR9 4 Portland, Oregon 97201, USA
    Expert Opin Drug Saf 4:29-44. 2005
  4. doi request reprint The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients
    Ali Olyaei
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin J Am Soc Nephrol 6:664-78. 2011
  5. doi request reprint The old and new methods of assessing kidney function
    Jessica L Steffl
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code CR9 4, Portland, OR 97201, USA
    J Clin Pharmacol 52:63S-71S. 2012
  6. doi request reprint Drug dosing in the elderly patients with chronic kidney disease
    Ali J Olyaei
    Division of Nephrology and Hypertension, Oregon Health and Science University, 3314 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Clin Geriatr Med 25:459-527. 2009
  7. ncbi request reprint Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies
    A J Olyaei
    Division of Nephrology, Hypertension and Clinical Pharmacology, Oregon Health Sciences University and Solid Organ and Cellular Transplantation, Legacy Good Samaritan Hospital, Portland, Oregon 97201, USA
    Curr Opin Crit Care 7:384-9. 2001
  8. ncbi request reprint Renal toxicity of protease inhibitors
    A J Olyaei
    Division of Nephrology, Hypertension and Clinical Pharmacology, Oregon Health Sciences University, Portland 97201, USA
    Curr Opin Nephrol Hypertens 9:473-6. 2000
  9. ncbi request reprint Late mortality after orthotopic liver transplantation
    J M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, 3181 SW Sam Jackson Park Road, L590, Portland, OR 97201 3098, USA
    Am J Surg 181:475-9. 2001
  10. ncbi request reprint Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors
    A M de Mattos
    Transplantation Medicine Program, Oregon Health and Science University, Portland, Oregon, USA
    Kidney Int 70:757-64. 2006

Collaborators

Detail Information

Publications17

  1. ncbi request reprint HMG-CoA reductase inhibitors in chronic kidney disease
    A Olyaei
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Sciences University, 3181 SW Sam Jackson Park Road, Mail Code CR9 4, Portland, OR, 97201, USA
    Am J Cardiovasc Drugs 13:385-98. 2013
    ..Patients with CKD are often on medications that may interact with many of the cholesterol-lowering agents. Ensuring drug interactions are minimized is essential to the prevention of adverse events from the medications. ..
  2. doi request reprint A quantitative approach to drug dosing in chronic kidney disease
    Ali J Olyaei
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97201, USA
    Blood Purif 31:138-45. 2011
    ..By applying a quantitative approach, health care providers can improve pharmacotherapeutic outcomes while reducing adverse drug reactions...
  3. ncbi request reprint Cardiovascular complications of immunosuppressive agents in renal transplant recipients
    Ali J Olyaei
    Oregon Health Sciences University, Division of Nephrology, Hypertension, 3181 SW Sam Jackson Park Road, Mail Code CR9 4 Portland, Oregon 97201, USA
    Expert Opin Drug Saf 4:29-44. 2005
    ..Adverse reactions and drug-drug interactions should not be neglected when selecting an agent for treatment of cardiovascular risk factors in transplant recipients...
  4. doi request reprint The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients
    Ali Olyaei
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Science University, Portland, Oregon 97201, USA
    Clin J Am Soc Nephrol 6:664-78. 2011
    ..Elderly patients with CKD are at greater risk of adverse drug reactions, and therefore the lowest possible dose of statins should be used for the treatment of hyperlipidemia...
  5. doi request reprint The old and new methods of assessing kidney function
    Jessica L Steffl
    Division of Nephrology and Hypertension, Oregon State University and Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code CR9 4, Portland, OR 97201, USA
    J Clin Pharmacol 52:63S-71S. 2012
    ..Drug-dosing adjustments based on the various equations may differ. However, without clinical outcome data, it is yet to be determined whether these differences are clinically significant...
  6. doi request reprint Drug dosing in the elderly patients with chronic kidney disease
    Ali J Olyaei
    Division of Nephrology and Hypertension, Oregon Health and Science University, 3314 SW US Veterans Hospital Road, Portland, OR 97201, USA
    Clin Geriatr Med 25:459-527. 2009
    ..Thus, primary care providers must proceed with caution when prescribing drugs for elderly patients with kidney disease...
  7. ncbi request reprint Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies
    A J Olyaei
    Division of Nephrology, Hypertension and Clinical Pharmacology, Oregon Health Sciences University and Solid Organ and Cellular Transplantation, Legacy Good Samaritan Hospital, Portland, Oregon 97201, USA
    Curr Opin Crit Care 7:384-9. 2001
    ..New experiences with non-nephrotoxic agents and protocols including mycophenolate and sirolimus allow for early calcineurin inhibitor reduction or elimination without increasing the risk of allograft rejection...
  8. ncbi request reprint Renal toxicity of protease inhibitors
    A J Olyaei
    Division of Nephrology, Hypertension and Clinical Pharmacology, Oregon Health Sciences University, Portland 97201, USA
    Curr Opin Nephrol Hypertens 9:473-6. 2000
    ..If significant renal insufficiency persists, temporary indinavir withdrawal or switching to another protease inhibitor should be considered...
  9. ncbi request reprint Late mortality after orthotopic liver transplantation
    J M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, 3181 SW Sam Jackson Park Road, L590, Portland, OR 97201 3098, USA
    Am J Surg 181:475-9. 2001
    ..The aim of this study was to determine the incidence of late mortality and to identify the most common causes and risk factors associated with late mortality after OLTx...
  10. ncbi request reprint Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors
    A M de Mattos
    Transplantation Medicine Program, Oregon Health and Science University, Portland, Oregon, USA
    Kidney Int 70:757-64. 2006
    ..Modifiable factors such as duration of dialysis, deceased-donor transplantation, and acute rejection should be viewed as cardiovascular risks...
  11. ncbi request reprint Tacrolimus is associated with a lower incidence of cardiovascular complications in liver transplant recipients
    J M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University and Portland Veterans Affairs Medical Center, 3181 SW Sam Jackson Park Road, L590, Portland, OR 97201 3098, USA
    Transplant Proc 34:1557-8. 2002
  12. ncbi request reprint Use of basiliximab and daclizumab in kidney transplantation
    A J Olyaei
    Oregon Health Sciences University, Portland, Ore, USA
    Prog Transplant 11:33-7; quiz 38-9. 2001
    ..Further studies are needed to evaluate the overall effect of these agents on long-term patient and allograft survival...
  13. ncbi request reprint Immunosuppression impact on long-term cardiovascular complications after liver transplantation
    John M Rabkin
    Department of Surgery, Division of Abdominal Organ Transplantation, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd L590, Portland, Oregon 97201 3098, USA
    Am J Surg 183:595-9. 2002
    ..Cardiovascular disease and associated risk factors have been shown in renal transplant patients to be related to the pharmacologic immunosuppression employed...
  14. ncbi request reprint Fatal fulminant hepatitis associated with bromfenac use
    J M Rabkin
    Department of Surgery, Oregon Health Sciences University, and Portland Veterans Affairs Medical Center, 97201, USA
    Ann Pharmacother 33:945-7. 1999
    ..To report a case of fulminant hepatic failure associated with the use of bromfenac, a new analog of the phenyl acetate class of nonsteroidal antiinflammatory drugs...
  15. ncbi request reprint Autosomal-dominant polycystic kidney disease as a risk factor for diabetes mellitus following renal transplantation
    Angelo M de Mattos
    Renal Transplant Program, Oregon Health and Science University, Portland, Oregon, USA
    Kidney Int 67:714-20. 2005
    ..The association between ADPKD and posttransplant diabetes mellitus has not been previously studied in a large cohort of patients...
  16. ncbi request reprint Hepatitis C infection increases the risk of new-onset diabetes after transplantation in liver allograft recipients
    Jordana L Soule
    Department of Surgery, Division of Liver Pancreas Transplantation, Oregon Health and Science University, 8131 SW Sam Jackson Park Road, L590, Portland, OR 97239, USA
    Am J Surg 189:552-7; discussion 557. 2005
    ..The objective of this study is to evaluate the effect of hepatitis C infection on the natural history of NODAT...
  17. ncbi request reprint Graft failure from severe recurrent primary sclerosing cholangitis following orthotopic liver transplantation
    Deepak V Gopal
    Division of Gastroenterology and Hepatology, Oregon Health Sciences University and Portland VA Medical Center, Portland, Oregon 97207, USA
    J Clin Gastroenterol 37:344-7. 2003
    ..Most reports of PSC recurrence post-OLT estimate rates of 1% to 14%, but to date, no center has reported rapidly progressive fibro-obliterative cholangitis leading to graft failure...